Market Overview

Citigroup Maintains Hold Rating On Acorda Therapeutics (ACOR)

Analysts at Citigroup have recommended that investors ‘Hold’ for Acorda Therapeutics (NASDAQ: ACOR). The target price for the biopharmaceutical company is at $39.00.

Analysts are positive about the launch of Ampyra, an Acorda product, which has received rosy reviews from the medical community. However, the demand backlog on Ampyra is a point of concern, but Acorda is working on it.

Additionally, Acorda received a non-final rejection on one of its 24 filed patents. Acorda, on the other hand, says that the rejection is routine and that they would reply back in 6 months.

Posted-In: Analyst Color Analyst Ratings

 

Most Popular

Related Articles (ACOR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free